Reports bilateral ophthalmoplegia in a patient after neoadjuvant pembrolizumab, suggesting need for multidisciplinary management.
The role of immune checkpoint inhibition (ICI) therapy in the treatment of head and neck squamous cell carcinoma (HNSCC) is expanding with increased utilization of neoadjuvant and adjuvant pembrolizumab in the setting of locally advanced disease. This report describes the presentation and management of the first known case of pembrolizumab-induced isolated bilateral ophthalmoplegia in a patient with locally advanced oral cavity squamous cell carcinoma. Multidisciplinary teams, including head and neck surgeons, are integral to the management of treatment-related complications following ICI therapy, and comprehensive guidelines are necessary optimize outcomes for patients with HNSCC.
No takes yet. Share an insight, caveat, or question.
Estephan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: